MidMarketNow
Get the Weekly

EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund, M Ventures

—

SectorsHealthcare1
RegionsEurope1
Last activity

Activity, last 12 months

EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund, M Ventures — deals per month, last 12 months
EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund, M Ventures — deals per month, last 12 months
MonthDeals
August 20250
September 20250
October 20250
November 20250
December 20251
January 20260
February 20260
March 20260
April 20260
May 20260
June 20260
July 20260

Deal history

  1. FoRx raises EUR 50m to push PARG inhibitor into Phase I

    Swiss precision oncology biotech FoRx Therapeutics has secured a EUR 50 million Series A led by repeat backers EQT Life Sciences, Novartis Venture Fund and Pfizer Ventures, with M Ventures participating. Proceeds fund Phase I development of lead asset FORX-428 with data expected by mid-2026.

We use privacy-respecting product analytics to understand how readers use MidMarketNow and improve it. No personal data (email, IP) is sent. See our privacy policy.